Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- Health Sciences Council to Upgrade Committee on Immunization to “Department on Preventive Vaccination and Vaccines”
February 7, 2013
- NIHS to Accelerate Medical Innovation Research
February 7, 2013
- MHLW to Launch Panel on Feb. 14 to Set New Rules for Online OTC Drug Sales
February 6, 2013
- New Council on Conflicts of Interest Holds 1st Meeting, Some Doctors Say Disclosure of Individual Payments, Recipient Names “Hasty”
February 5, 2013
- Takeda, KAKETSUKEN Apply for Funding Under Second Project to Develop and Manufacture New Flu Vaccines
February 4, 2013
- PAFSC's 2nd Committee Recommends Approval for Arzerra
February 1, 2013
- CRO Association to Compile Guidelines for Third-Party Outsourcing after GCP Revision
February 1, 2013
- Government Allocates 9 Billion Yen in FY2013 Budget to Boost Reviews and Safety Measures of Pharmaceutical Products
January 31, 2013
- Japan Cabinet OKs FY2013 Budget, Social Security Outlays Nearly 29 Trillion Yen
January 30, 2013
- 13 Generic Makers Slapped with Improvement Order due to South Korean Supplier’s GMP Violation
January 30, 2013
- Membership of Committee on Non-Prescription Drugs to Be Evenly Split Between Medical, Pharmaceutical Communities
January 30, 2013
- Ordinary Diet Session Convenes; Bills to Amend Preventive Vaccination Law, Public Assistance Law Expected to Be Submitted
January 30, 2013
- Welfare Recipients Will Be Required to Use Generics from April 1; Those Who Request Original Drugs Will Be Asked to Give Reason
January 29, 2013
- Ministers of Health, Finance, and Internal Affairs Agree to Add 3 Vaccines to Public Vaccination Programs in April
January 29, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of Japan’s First FD Treatment
January 28, 2013
- Preliminary Meetings of Regulatory Consultations Reach 331, Increase Found in Central and Peripheral Nervous System Drugs
January 25, 2013
- New Government Economic Panel Holds First Meeting, Takeda President Hasegawa Proposes to Bring Competition to Medical Industry
January 25, 2013
- Premium for New Drug Development to Be Discussed Alongside Long-Listed Drugs, Development of Drugs Used Off-Label: Health Minister Tamura
January 25, 2013
- Draft Basic Policy for FY2013 Budget Calls for “Prioritization” in Social Security to Minimize Increase in Public Burden
January 24, 2013
- MHLW Proposes Adding Test for Alcohol Consumption and Dependence to Health Checkup Program
January 24, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…